PFSA Profusa, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1859807 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY23.0%
TTM EPS YoY197.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-155.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets73.0%
Debt / equity0.00x
Current ratio0.02x
Interest coverage-174.12x
Cash quality & payout
Operating cash flow / net income0.47x
Accruals ratio-82.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $0 |
| R&D expense | $222,000 | $823,000 | $1.15M | $1.25M | $722,000 | $393,000 | $434,000 | $259,000 |
| SG&A expense | $4.63M | $1.72M | $2.86M | $2.31M | $20.99M | $610,000 | $990,000 | $823,000 |
| Operating income | -$4.85M | -$2.54M | -$4.01M | -$3.57M | -$21.71M | -$1.00M | -$1.42M | -$1.08M |
| Interest expense | $22,000 | $21,000 | $18,000 | $25,000 | $169,000 | $1.19M | $1.14M | $1.29M |
| Pretax income | — | — | — | — | — | -$8.19M | -$1.10M | -$7.57M |
| Income tax | — | — | — | — | — | $2,386 | $19,352 | $16,534 |
| Net income | -$4.95M | -$8.76M | -$3.46M | -$8.57M | -$26.09M | -$2.35M | -$2.72M | -$2.25M |
| EBITDA | -$4.85M | — | — | — | — | — | — | — |
| EPS (basic) | -6.23 | -151.80 | -2.05 | — | -6,167.85 | -9,100.78 | -105.09 | — |
| EPS (diluted) | -6.23 | -151.80 | -2.05 | — | -6,167.85 | -9,100.78 | -105.09 | — |
| Weighted avg. shares (diluted) | 794,920 | 57,676 | 1.69M | — | 4,230 | 258 | 25,844 | — |
| Banking | ||||||||
| Deposits | — | — | — | — | — | $29,171 | $13,162 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $339,000 | $719,000 | $375,000 | $1.78M | $3.01M | $39,000 | $19,000 | $191,000 |
| Current assets | $394,000 | $841,000 | $662,000 | $3.76M | $4.20M | $687,867 | $63,183 | $260,000 |
| PP&E, net | $80,000 | $84,000 | $13,000 | $8,000 | — | — | — | — |
| Total assets | $28.89M | $1.04M | $862,000 | $3.77M | $4.25M | $1.96M | $1.98M | $3.07M |
| Current liabilities | $21.09M | $28.17M | $29.02M | $22.26M | $23.54M | $16.18M | $13.25M | $57.13M |
| Total liabilities | $21.09M | $28.17M | $29.06M | $30.43M | $38.21M | $23.14M | $14.30M | $57.13M |
| Shareholders' equity | $7.79M | -$27.13M | -$28.20M | -$26.66M | -$33.91M | -$124.18M | -$121.92M | -$119.20M |
| Shares outstanding | 2.52M | 132,308 | 2.38M | 12,320 | 41.73M | 5.19M | 5.19M | 25,844 |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.68M | -$2.63M | -$2.58M | -$5.13M | -$10.62M | -$589,000 | -$537,000 | -$238,000 |
| Capital expenditure | $1,000 | $73,000 | $5,000 | — | — | — | — | — |
| Free cash flow | -$1.68M | -$2.71M | -$2.58M | — | — | — | — | — |
| Investing cash flow | -$1,000 | -$73,000 | $1.15M | -$1.01M | -$7.49M | -$1 | $6.49M | $457,936 |
| Financing cash flow | $1.30M | $3.05M | $28,000 | $4.91M | $20.94M | $609,000 | $365,000 | $289,000 |
| Depreciation & amortization | $5,000 | — | — | — | — | — | — | — |
| Stock-based compensation | $126,000 | $188,000 | $187,000 | $187,000 | $617,000 | $82,000 | $5,000 | $5,000 |
| Share buybacks | — | — | — | — | — | $0 | $6.51M | $595,439 |
Free plan shows the latest 8 periods; Pro shows all 21 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.